Amaranth Medical: Amaranth Medical looks to recapture the potential of bioresorbable scaffolds

Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical's Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events. He told the EuroPCR attendee that they hadn't seen any adverse events related to the device during the trial - and that's unusual. Bioresorbable scaffolds, like Abbott's (NYSE:ABT) Absorb, have been [...]The post Amaranth Medical looks to recapture the potential of bioresorbable scaffolds appeared first on MassDevice.